Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma CoDNPUF 51 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates DNPUF with a GF Score™ of 51/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 785 Drug Manufacturers companies, Sumitomo Pharma Co ranks worse than 127388.41% on this metric.
During the past 12 months, Sumitomo Pharma Co's average EPS without NRI Growth Rate was 352.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Sumitomo Pharma Co was 95.60% per year. The lowest was -41.80% per year. And the median was 8.90% per year.
Sumitomo Pharma Co (OTCPK:DNPUF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Sumitomo Pharma Co 3-Year EPS without NRI Growth Rate Related Terms
DNPUF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's 3-Year EPS without NRI Growth Rate falls into.
Sumitomo Pharma Co 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Sumitomo Pharma Co (DNPUF) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sumitomo Pharma Co and its competitors. According to the industry distribution chart, Sumitomo Pharma Co ranks #999999 out of 785 companies in the Drug Manufacturers industry.
Is Sumitomo Pharma Co's 3-Year EPS without NRI Growth Rate too high?
Sumitomo Pharma Co's current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Sumitomo Pharma Co ranks #999999 out of 785 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sumitomo Pharma Co has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #999999 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places Sumitomo Pharma Co in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $9.79 — trading 71.8% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.00%. Sumitomo Pharma Co's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of $9.79 is trading 71.8% above its estimated GF Value™ of $5.70.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for DNPUF:
3-Year EPS without NRI Growth Rate: 0.00%
GF Value™: $5.70 vs. price of $9.79 (71.8% above fair value)
No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
51GF Score
Get the complete analysis for DNPUF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNPUF has been successfully added to your 
